Loading stock data…
SNN
$31.32+0.98 (+3.23%)
After Hours$31.32+0.00 (+0.00%)· Last close Jun 9
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Smith & Nephew plc in the Healthcare sector is trading at $31.32 with a market capitalization of $12.7B. Wall Street consensus targets $34.99 (5 analysts), implying a +11.7% move over the next 12 months. The stock is currently 19% below its 52-week high of $38.79, remaining 6.3% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +11.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$31.32
Potential Downside
9.2%
Whystock Fair Value$28.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Me...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.72B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.93
Beta
Defensive asset. Lower volatility than the S&P 500.
0.67
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.49%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
1.36M
Recent News
Smith & Nephew and 4 More Stocks See Action From Activist Investors
Activists also report to the SEC on Groupo Aeroportuario del Sureste, Constellium, Satellogic, and Oorvo.
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were declining late Wednesday mor
Bernstein Cuts PT on Smith & Nephew plc (SNN)
Smith & Nephew plc (NYSE:SNN) is one of the best robotic surgery stocks to buy. Bernstein cut the price target on Smith & Nephew plc (NYSE:SNN) to $31.85 from $36.20 on May 11, maintaining a Market Perform rating on the shares. The rating update came after the company provided a fiscal Q1 trading update on May […]
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were trending lower late Tuesday
Medical Device Stocks Are Ready to Bounce. Two Names to Buy Now.
Glaukos, a medical technology company focusing on eye disorders, has achieved gains of 20% year to date and 48% over the last year.